BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 23019224)

  • 21. Nucleophosmin 1, upregulated in adenomas and cancers of the colon, inhibits p53-mediated cellular senescence.
    Wong JC; Hasan MR; Rahman M; Yu AC; Chan SK; Schaeffer DF; Kennecke HF; Lim HJ; Owen D; Tai IT
    Int J Cancer; 2013 Oct; 133(7):1567-77. PubMed ID: 23536448
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic inactivation of the transcription factor TIF-IA leads to nucleolar disruption, cell cycle arrest, and p53-mediated apoptosis.
    Yuan X; Zhou Y; Casanova E; Chai M; Kiss E; Gröne HJ; Schütz G; Grummt I
    Mol Cell; 2005 Jul; 19(1):77-87. PubMed ID: 15989966
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells.
    Roberts AM; Watson IR; Evans AJ; Foster DA; Irwin MS; Ohh M
    Cancer Res; 2009 Dec; 69(23):9056-64. PubMed ID: 19920202
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Wnt antagonist DKK1 acts as a tumor suppressor gene that induces apoptosis and inhibits proliferation in human renal cell carcinoma.
    Hirata H; Hinoda Y; Nakajima K; Kawamoto K; Kikuno N; Ueno K; Yamamura S; Zaman MS; Khatri G; Chen Y; Saini S; Majid S; Deng G; Ishii N; Dahiya R
    Int J Cancer; 2011 Apr; 128(8):1793-803. PubMed ID: 20549706
    [TBL] [Abstract][Full Text] [Related]  

  • 25. P19ARF and RasV¹² offer opposing regulation of DHX33 translation to dictate tumor cell fate.
    Zhang Y; Saporita AJ; Weber JD
    Mol Cell Biol; 2013 Apr; 33(8):1594-607. PubMed ID: 23401854
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation.
    Kurki S; Peltonen K; Latonen L; Kiviharju TM; Ojala PM; Meek D; Laiho M
    Cancer Cell; 2004 May; 5(5):465-75. PubMed ID: 15144954
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The polymorphisms of P53 codon 72 and MDM2 SNP309 and renal cell carcinoma risk in a low arsenic exposure area.
    Huang CY; Su CT; Chu JS; Huang SP; Pu YS; Yang HY; Chung CJ; Wu CC; Hsueh YM
    Toxicol Appl Pharmacol; 2011 Dec; 257(3):349-55. PubMed ID: 21982800
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autocrine interleukin-6 production in renal cell carcinoma: evidence for the involvement of p53.
    Angelo LS; Talpaz M; Kurzrock R
    Cancer Res; 2002 Feb; 62(3):932-40. PubMed ID: 11830554
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overexpression of DLC-1 induces cell apoptosis and proliferation inhibition in the renal cell carcinoma.
    Zhang T; Zheng J; Jiang N; Wang G; Shi Q; Liu C; Lu Y
    Cancer Lett; 2009 Sep; 283(1):59-67. PubMed ID: 19380190
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of an aberrantly spliced form of HDMX in human tumors: a new mechanism for HDM2 stabilization.
    Giglio S; Mancini F; Gentiletti F; Sparaco G; Felicioni L; Barassi F; Martella C; Prodosmo A; Iacovelli S; Buttitta F; Farsetti A; Soddu S; Marchetti A; Sacchi A; Pontecorvi A; Moretti F
    Cancer Res; 2005 Nov; 65(21):9687-94. PubMed ID: 16266988
    [TBL] [Abstract][Full Text] [Related]  

  • 31. UBTD1 induces cellular senescence through an UBTD1-Mdm2/p53 positive feedback loop.
    Zhang XW; Wang XF; Ni SJ; Qin W; Zhao LQ; Hua RX; Lu YW; Li J; Dimri GP; Guo WJ
    J Pathol; 2015 Mar; 235(4):656-67. PubMed ID: 25382750
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of DHX33 as a mediator of rRNA synthesis and cell growth.
    Zhang Y; Forys JT; Miceli AP; Gwinn AS; Weber JD
    Mol Cell Biol; 2011 Dec; 31(23):4676-91. PubMed ID: 21930779
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The balance between rRNA and ribosomal protein synthesis up- and downregulates the tumour suppressor p53 in mammalian cells.
    Donati G; Bertoni S; Brighenti E; Vici M; Treré D; Volarevic S; Montanaro L; Derenzini M
    Oncogene; 2011 Jul; 30(29):3274-88. PubMed ID: 21399665
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polyoma virus disrupts ARF signaling to p53.
    Lomax M; Fried M
    Oncogene; 2001 Aug; 20(36):4951-60. PubMed ID: 11526480
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CNPY2 promoted the proliferation of renal cell carcinoma cells and increased the expression of TP53.
    Taniguchi H; Ito S; Ueda T; Morioka Y; Kayukawa N; Ueno A; Nakagawa H; Fujihara A; Ushijima S; Kanazawa M; Hongo F; Ukimura O
    Biochem Biophys Res Commun; 2017 Apr; 485(2):267-271. PubMed ID: 28235487
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protein phosphatase 1 nuclear targeting subunit is a hypoxia inducible gene: its role in post-translational modification of p53 and MDM2.
    Lee SJ; Lim CJ; Min JK; Lee JK; Kim YM; Lee JY; Won MH; Kwon YG
    Cell Death Differ; 2007 Jun; 14(6):1106-16. PubMed ID: 17318220
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PBRM1 (BAF180) protein is functionally regulated by p53-induced protein degradation in renal cell carcinomas.
    Macher-Goeppinger S; Keith M; Tagscherer KE; Singer S; Winkler J; Hofmann TG; Pahernik S; Duensing S; Hohenfellner M; Kopitz J; Schirmacher P; Roth W
    J Pathol; 2015 Dec; 237(4):460-71. PubMed ID: 26178300
    [TBL] [Abstract][Full Text] [Related]  

  • 38. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
    Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F
    Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma.
    Morris MR; Gentle D; Abdulrahman M; Maina EN; Gupta K; Banks RE; Wiesener MS; Kishida T; Yao M; Teh B; Latif F; Maher ER
    Cancer Res; 2005 Jun; 65(11):4598-606. PubMed ID: 15930277
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regulation of angiogenic factors by HDM2 in renal cell carcinoma.
    Carroll VA; Ashcroft M
    Cancer Res; 2008 Jan; 68(2):545-52. PubMed ID: 18199551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.